Keyomarsi K - Search Results

1

Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Bedrosian I, et al. Among authors: keyomarsi k. Oncogene. 2004 Apr 8;23(15):2648-57. doi: 10.1038/sj.onc.1207408. Oncogene. 2004. PMID: 15007381

2

Inhibition of cyclin-dependent kinases by p21.

Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, et al. Harper JW, et al. Among authors: keyomarsi k. Mol Biol Cell. 1995 Apr;6(4):387-400. doi: 10.1091/mbc.6.4.387. Mol Biol Cell. 1995. PMID: 7626805 Free PMC article.

3

Deregulation of cyclin E in breast cancer.

Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP. Keyomarsi K, et al. Oncogene. 1995 Sep 7;11(5):941-50. Oncogene. 1995. PMID: 7675453

4

Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.

Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K. Bacus SS, et al. Among authors: keyomarsi k. Oncogene. 1996 Jun 20;12(12):2535-47. Oncogene. 1996. PMID: 8700512

5

Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.

Rao S, Lowe M, Herliczek TW, Keyomarsi K. Rao S, et al. Among authors: keyomarsi k. Oncogene. 1998 Nov 5;17(18):2393-402. doi: 10.1038/sj.onc.1202322. Oncogene. 1998. PMID: 9811471

6

Cyclin E and survival in patients with breast cancer.

Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Keyomarsi K, et al. N Engl J Med. 2002 Nov 14;347(20):1566-75. doi: 10.1056/NEJMoa021153. N Engl J Med. 2002. PMID: 12432043 Free article.

7

Cyclin E is a more powerful predictor of breast cancer outcome than proliferation.

Keyomarsi K, Tucker SL, Bedrosian I. Keyomarsi K, et al. Nat Med. 2003 Feb;9(2):152. doi: 10.1038/nm0203-152. Nat Med. 2003. PMID: 12563321 No abstract available.

8

The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells.

Wingate H, Bedrosian I, Akli S, Keyomarsi K. Wingate H, et al. Among authors: keyomarsi k. Cell Cycle. 2003 Sep-Oct;2(5):461-6. Cell Cycle. 2003. PMID: 12963845

9

Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.

Akli S, Keyomarsi K. Akli S, et al. Among authors: keyomarsi k. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S38-47. Cancer Biol Ther. 2003. PMID: 14508079 Review.

10

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Akli S, et al. Among authors: keyomarsi k. Cancer Res. 2004 May 1;64(9):3198-208. doi: 10.1158/0008-5472.can-03-3672. Cancer Res. 2004. PMID: 15126360

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146 results

Search Page

Filters